. Growth curves of untreated and olaparib-treated primary MDS and normal progenitor cell cultures. (A)Bone marrow samples collected from 4 MDS patients were treated with increasing concentrations of olaparib and cultured for 7 days. The indicated MDS samples were characterized by comparable olaparib IC50 values (ID-75, ID-04, ID-41 and ID-42 olaparib IC50s: 4.2, 3.9, 3.8 and 4 µ M, respectively), but different proliferation rates. (B) BM, CD34-enriched mobilized peripheral blood samples and purified CD34+ cells were obtained from healthy donors and exposed to the indicated concentrations of olaparib for 7 days. BM, CD34-enriched (1) and (2), purified CD34+ cells olaparib IC50s: 20.8, 27.0, 26.1, 18.5 µ M, respectively. Bars = SD.
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